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Device closure is now an accepted modality of treatment for cardiac septal defects such as
fossa ovalis Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD) and Patent Ductus
Arteriosus (PDA) and have well-accepted indication and long term results. Devices used for
these defects have been specifically designed for use in closing these defects. In this
manuscript, we are reporting the efficacy of closure of nonseptal defects with devices
conventionally used for septal cardiac defects although they have not been prototyped for
use in such conditions.
Aim: To study use of occluder devices in nonseptal defects/malformation.
Material &methods: 39 patients, in the age group 2e67 yrs, were treated percutaneously with
occluder devices for various conditions. These included: coronary arteriovenous (CAV)
fistula (n ¼ 6), pulmonary AV fistula (n ¼ 4), systemic AV fistula (vascular plug; n ¼ 1),
closure of AP window (duct occluder; n ¼ 3), closure of ascending aorta perforation (septal
occluder; n ¼ 2), ruptured sinus of Valsalva (RSOV) (duct occluder; n ¼ 13), Fontan fenes-
tration closure (ASD septal occluder, patent foramen ovale device, vascular plug n ¼ 3,1
each), splenic artery (duct occluder; n ¼ 1), Balock Taussig shunt (duct occlude; n ¼ 1)and
closure of mitral paravalvular leak (n ¼ 3; duct occlude devices ¼ 2, VSD device: n ¼ 1) and
aortic paravalvular leak n ¼ 2 (duct occluder; n ¼ 2 additional vascular plug ¼ 2).
Results: Procedural success: Successful closure as signified by no residual shunt was ach-
ieved in all coronary AV fistula (immediately n ¼ 2, at 3 months in all), ruptured sinus of
Valsalva (immediate in all), fenestrated Fontan (immediately in all), and ascending aorta
perforations (immediate), mitral paravalvular leak (immediate in none, and late in 2/3). The
aortic paravalvular leak closed at 3 months follow-up in one and small residual persisted
after 1 month in another. Complications: Local site Hematoma was observed in 4 patients.
2 of them required post procedure transfusion for the same. Hematuria was observed in 2
of the 4 patients of mitral paravalvular leak and 2 patients of RSOV device closure. He-
maturia subsided with conservative management before discharge from hospital in all the775.
N. Awasthy).
ciety of India. All rights reserved.
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 1 2 8e1 3 5 1294 cases. One patient with residual mitral regurgitation required surgical management for
continuing hematuria, anemia and hyperbilirubenemia. There was one mortality observed
on table during the attempted closure of a very large RSOV who presented to us in severe
congestive heart failure and shock. On follow up ranging from 2 months to 6 years, all the
patients are asymptomatic. There was no late complication related to device in any patient.
Conclusion: It is feasible in selected nonseptal defects, which traditionally have been sub-
jected to surgical interventions, to treat successfully, non surgically with the use of non
prototype occluder devices without significant complications. Conventionally these de-
vices have not been recommended for closure of nonseptal defects but show good early
outcome. Adequate sample size with good follow up data is necessary before concluding
that it can be safe alternative to surgery on long term.
Copyright © 2015, Cardiological Society of India. All rights reserved.1. Introduction
Transcatheter closure of septal defects (fossa ovalis ASD, VSD,
PDA) is a recognizedmodality for treatment of cardiac defects.
With increasing experience, unconventional use of these de-
vices in defects other than septal defects is now increasing.
Here we are reporting our experience of these devices in car-
diac and extracardiac defects/malformation and review the
available literature for their usage in the current era.2. Methods
2.1. Patient population
From June 2001 to April 2013 39 patients were included.
2.2. Exclusions
Unconventional methods of device deployment at conven-
tional sites like hybrid approaches for VSD devices have been
excluded from the manuscript. Excluded from the study were
venous channels closed with vascular plugs, major aorto-
pulmonary collaterals (MAPCA), PDA who underwent coil or
vascular plug closures have also been excluded. An informed
writtenconsentwas takenfromall thepatientsor theirparents.
2.3. The device
The devices used included, Amplatzer Septal Occluder and
delivery system (AGA Medical, Golden Valley, Minnesota),
Lifetech (Heart R) device systems and delivery system (ASD,
VSD, PDA). Amplatzer vascular plug (generation 1,2 and 4). All
the devices have been described in detail in other reports (2,6).
There are well documented standardized protocol for the
deployment of the respective devices with multiple series
describing the efficacy and safety of the device at conven-
tional sites.
2.4. Patient's selection for transcatheter closure
Selection of patients suitable for device closure was based on
measurement of maximal defect diameter done using variousinvestigational modalities like echocardiography, Computer-
ized Tomography (CT) angiography, Magnetic resonance im-
aging (MRI) and angiography. It was also based on
morphological characteristics like location and size of the
defect, relationship with the adjoining structures and rims of
the defect.2.5. Protocol for all patients
Detailed clinical and physical examinations, a standard 12-
lead electrocardiogram (ECG), chest radiograph, transthoracic
echocardiography (TTE) were performed in all patients. In
patients with poor echo windows (adolescents and adults) or
whenever it was needed to define the morphological charac-
teristics of the defect, transesophageal echocardiography
(TEE), CT angiography or MRI and angiography was also done
if necessary for anatomical definition.2.6. Implantation procedure
The procedure was done in catheterization laboratory under
general anesthesia/local anesthesia in most of the patients
with or without echocardiography and fluoroscopy guidance
(Table 1). After obtaining the venous and arterial access, 100
units/kg of unfractionated Heparin is given to all the patients.
Right heart hemodynamic data is obtained in all the patients
prior to the procedure.2.7. Follow up protocol
Detailed echocardiography examination was performed
immediately after device closure in all patients to check for
device position, stability, encroachment of device on
adjoining structures. Flow through device fabrics was com-
mon at the time of device deployment and was not taken as
residual shunt while any additional jet of shunt was taken as
residual shunt. At 24 h Chest X-ray (Deep penetrating, frontal
and lateral views), and transthoracic echocardiography were
performed. On TTE, device position, stability, any evidence of
encroachment over adjoining structures was checked. Bacte-
rial endocarditis prophylaxis was advised for 6 months post
procedure. Thereafter, follow up was done at 1 month, 3
months, 1 year and then annually with clinical evaluation,
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symptomatic evaluation.3. Results
A total of 39 patients were included. The details of the indi-
vidual sites have been describes as below:3.1. Fistulae: coronary, pulmonary and systemic
3.1.1. Coronary AV fistulae
7patients underwent coronary AV fistulae using interven-
tional techniques (in cath lab). 3 patients underwent the
closure with PDA ductal occluder device, 4 patients under-
went coil closure of the coronary AV fistula. 2 of the latter
patients had vascular plug occlusion of the defect followed by
the additional coil closure of the same in view of the residual
flow. Demographic profile is summarized in Table 2. Mean
follow up is 3.6 years (ranging from 1 to 10 years). One 22 year
old young girl had the fistulae closure in multiple sittings as
there were additional openings of the coronary fistulae, which
became apparent only after the closure of the fistulaous tracts.
Case highlighted a proper evaluation preferably with a CT
reconstruction to define the course of the fistulae. All patients
underwent complete closure of the defect with no residual
shunt. There was no associated ECG changes or vascular
complications.
3.1.2. Systemic and pulmonary AV fistulae
A total of 5 patients were included in the group. Of these 2
underwent systemic AV fistula closure while 3 patients un-
derwent pulmonary AV fistulae closure. Complete closurewas
achieved in all the patients (Table 3). A 4month old boy (case1,
Table 3) had abnormal fistulous connection between the
proximal right subclavian artery to upper end of SVC, a rare
communication. Amplatzer Vascular plug (6 mm) occlusion
which was deployed from right subclavian artery under fluo-
roscopic guidance with complete occlusion of the abnormal
fistulous tract was achieved. He also required associated SVC
stenting because of the constriction in SVC at the site of fis-
tulous insertion.1Of all the patients of pulmonary AV fistulae
(n ¼ 8)who underwent transcatheter closure, four had closureTable 1 e Showing the summarization of cases with respect to
used for the same (n ¼ 39).
Site
1 Coronary AV fistula
2 Systemic & pulmonary
3 RSOV
4 Fenestration Fontan
5 Paravalvular leak (mitral þ aortic)
6 AP Window
7 Ascending aortic perf
8 Splenic artery occlusion
9 BT shunt
(TTE: transthoracic echocardiography, TEE: Transesophageal echocard
arteriosus).of the fistulae using the ductal occluder (detailed in Table 3),
using the ductal occluder 18  16 mm (Heart R, Lifetech) in all
the cases. It was done successfully with no residual shunt.
Patient hadmean systemic saturation of 75%which increased
to mean systemic saturations of 97% in the catheterization
laboratory immediately after procedure. Patients are doing
well with no complications and saturations are maintained at
follow up An interesting case of a 20 year old girl (Case 2) who
was deeply cyanosed was evaluated to have multiple pulmo-
nary av fistulae which were closed by 2 ductal occluders and
additional third fistulae was closed by a vascular plug. It is
thus important to evaluate the presence of additional AV
fistulae in any case of pulmonary AV fistulae.3.2. RSOV
13 patients (11 males and 2 female) with RSOV underwent
transcatheter device closure during the study period. The
mean age was 41 years (21e59 years). All the patients had
shortness of breath (NYHA class II e eight patients, class III e
two patients) at the time of presentation. Two patients (25.0%)
presented with acute exacerbation of symptoms and cardiac
failure. The sites of origin and exit of RSOV are summarized in
Table 4. Noncoronary cusps were sites of origin in 10/13 pa-
tients while it was from right coronary sinus in 3 patients. The
site of exit was into the right atrium in 10/13 patients and right
ventricular outflow tract (3/13). The PDA devices used for
RSOV closure were 16/14 (9/13), 12/14 (1/13), 10/12 (1/13) and 8/
10 (1/13). The mean procedural time was 45.3 ± 5.4 min, while
the fluoroscopic time was 26.5 ± 6.9 min. All patients under-
going device closure were extubated electively after 4e6 h
following the procedure. Complete closure was achieved in all
the patients.
One patient with biventricular dysfunction (case1 not
included in Table 4), acute renal failure, and thrombocyto-
penia had cardiac arrest in an attempted crossing of the RSOV.
Follow up is available for all patients with mean follow up of
2.5 years (1 monthse7 years). At the time of the most recent
follow-up, all the device-closure patients were in NYHA
symptom class I. Clinical evaluation revealed stable hemo-
dynamics with absence of murmur in all. Their ECGs did not
reveal any ischemia, conduction abnormalities, or rhythm
disturbances. Two-dimensional echocardiography revealedthe type of cases, their imagingmodalities and the sedation
Device Sedation Imaging
6 LA TTE, Floro
5 LA TTE (1), Floro
13 GA and LA TEE, Floro
3 GA TTE, Floro
3 þ 2 GA TEE, Floro
3 GA TTE, Floro
2 GA Floro
1 GA Floro
1 GA Floro
iography, Floro: Floroscopy and angiography, PDA: Patent ductus
Table 2 e Coronary AV fistulae: table showing our experience with Coronary AV fistulae devices.
Age (yrs) Sex Device size Device type Follow up
1 53 F .018  3  3 Coil 1 yrs
2 57 F 10/12 mm PDA device HRT R 5 yrs
3 2 M 0.38, 5  5 GT COOK COIL 10 yrs
4 1 yrs 7 months M 8 mm vascular plug (additional 3 coils) Vascular plug 1 yrs
5 45 M 10/12 PDA 2 yrs
6 45 F 0.38  5  5 Coil 3 yr
7 20 M 10/12 PDA 1 yr
8 22 F PDA devices; 2, Vascular plug 1 1 yr
(M: male, F: female, PDA: patent ductus arteriosus, HRT R: Lifetech heart e R device).
Table 3 e Pulmonary And Systemic AV Fistula: table showing our experience with devices.
Age Sex Primary diagnosis Device size Device type
1 4 months Male av fistula, rsca to SVC 6 mm Vascular plug
2 20 yrs Male PAVF 18  16 mm,
8  10, Plug size 10 mm
PDA device, PDA device Hert R,
Vascular Plug: Amplatzer
3 28 yrs Female SAVF: left shoulder joint
(brachial artery, axillary artery.)
0.35  4  3 Cook coil, PDA
4 20 F PAVF 0.38  5  5, 18  16 Cook Coil, PDA
5 21 M PAVF 18  16 Cook coil, PDA
(RSCA: right subclavian artery, SVC: superior vena cava, SAVF: systemic arteriovenous fistulae, AV: arteriovenous, PAVF: pulmonary AV
fistulae).
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residual shunt, in all the patients. There was no neo-AR.
Three of our patients had an RSOV to right ventricular
outflow tract (RVOT). There was kinking of the sheath at the
point of crossing of the sheath from right ventricle (RV) to
aorta.We overcome the difficulty by using “Kissing technique”
(where in a multipurpose A2 (MPA2) catheter was advanced
from the arterial end into the sheath). As the device was
advanced the MPA2 catheter was withdrawn simultaneously
in order to overcome the kink (case 5). Another modification
we did for the case was passing a buddy wire (0.018 coronary
wire) across which was passed prior to the deployment of the
device, across the sheath. This not only gave support while
deploying the device, it was also a useful access to the siteTable 4 e RSOV: table showing details of patient who underwe
Age (yr) Sex RSOV to Sinus
1 40 M RA NCC
2 21 M RA RCC
3 23 M RA NCC
4 38 M RA NCC
5 57 M RVOT ?NCC
6 59 F ra NCC
7 52 M ra NCC
8 46 M ra NCC
9 40 M RA NCC
10 35 F RA NCC
11 25 M RVOT RCC
12 24 M RVOT RCC
(RSOV: ruptured sinus of valsalve, NCC: non coronary cusp, RCC: right c
right ventricular outflow tract).even after the device sheath assembly has been withdrawn
(Buddy wire technique) (case 5) (case 1).
3.3. FONTAN fenestration
Fontan fenestration was closed successfully in three patients.
The devices used were Patent foramen ovale (PFO) device
(18 mm), ASD septal occluder (Lifetech) device (6 mm) and
Vascular plug (4 mm) one each. The device was successfully
delivered in all 3 patients attempted with no major compli-
cation. Table 5 summarizes patient procedure detailed and
hemodynamic data. Arterial oxygen saturation and the ratio
of pulmonary to systemic blood flow increased significantly in
all patients.nt successful RSOV device closure.
Device size Device type Follow up
14/16 mm PDA (Ductal occluder) 2
14/16 mm PDA 3
14/12 mm PDA 3
14/16 mm PDA 5
14/16 mm PDA 1
14/16 mm PDA 1
14/16 mm PDA 7
14/16 PDA 1
14/16 PDA 1
14/16 PDA 6 months
10/12 PDA 1 month
8/10 PDA 1 month
oronary cusp, PDA: patent ductus arteriosus, ra: right atrium, RVOT:
Table 5 e Fontan fenestration closure (Demographic data).
Age
(yrs)
Sex Wt (kg) Primary diagnosis Previous surgery Device
size
Device used Pressures
rise
Spo2
rise
1 5 M 17.5 DILV, VSD, PS Primary Fontan ? 4 yrs 6 mm ASD device no 5%
2 25 F 75 Univentricular AV connection, PS 25 mm PFO device no 5%
3 16 F 70 Single outflow pulmonary
atresia hypoplastic, RV
BT shunt (6 months)
Fontan (4 yrs)
4 mm Vascular plug 4 no 4%
(DILV: double inlet left ventricle, VSD: ventricular septal defect, PS: pulmonary stenosis, ASD: atrial septal defect, BT: Ballock Taussing shunt,
RV: right ventricle).
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Device closure of paravalvular leak was attempted in 5 pa-
tients (Table 6). 3 patients underwent closure of mitral par-
avalvular leak, Two patients had aortic paravalvular leak. In
case of mitral paravalvular leak, 2 cases were crossed from
the left atrium after trans-septal puncture, the third case it
was crossed from the left ventricle and snared from left
atrium after trans-septal puncture. PDA device was used in 2
and VSD septal occluder in 1 patient. The device was
deployed successfully in all the 3 patients. Immediately post
device deployment the patients were extubated within 8 h.
2/3 patients of mitral paravalvular leak had hematuria
following the procedure which was conservatively managed.
It recovered in one patient while in another it required re-
operative intervention, 2 months later for persistent hema-
turia and residual paravalvular leak. In two cases of the
aortic paravalvular leak it was crossed retrogradely. In case 5
in a 56 year old man it required the usage of 2 additional
vascular plug to occlude the leak. Mild paravalvular leak
persisted in this patient after closure, even in follow up at 2
months.
3.5. AP window closure (Table 7)
3 patients underwent successful transcatheter closure of AP
window, Proximal type. It was attempted in 4 patients, while
in one 3 year old patient the procedure needed to be aban-
doned in view of in ability of the PDA device deployment;
patient successfully underwent direct ligation of the restricted
AP window. PDA ductal occluder was used in all the cases.6/
8mm in 2 cases and 4/6mm in 1patient. Complete closurewas
achieved in the catheterization lab in all the 3 successful
attempted cases.
3.6. Ascending aortic perforation closure
A 70 year old male who had undergone surgery (CABG) was
noticed to tachycardia, but stable hemodynamics. He was
observed to have mediastinal widening on chest x-ray. CTTable 6 e Paravalvular Device closure: Table showing our expe
Age (yrs) Sex Valve
1 65 M Mitral VSD
2 46 M Mitral PDA
3 55 F Mitral PDA
4 45 M Aortic PDA
5 56 M Aortic (status post DVR) PDAdone showed perforation of the ascending aorta. A retrograde
crossing of the perforation was done using right Judkins
catheter and termo wire. This was exchanged with an
appropriate sized sheath and thereafter successful device
closure using 8 mm ASD device, retrograde through aorta.
Patient was discharged successfully in an asymptomatic state
but no follow up data is available for the same. Another 50
year old post Bentall patient presented with pseudoaneurysm
of the ascending aorta which was closed successfully using
ASD device.
3.7. BT shunt occlusion with the device
A newborn 12 days old male child case of valvular pulmonary
atresia with intact ventricular septum had surgical valvotomy
and right BT shunt surgery successfully. Child was extubated
and discharged after 12th postoperative day. He was regularly
followed up and electively admitted at 18months of agewhere
in he underwent Balloon valvuloplasty, closure of the BT
shunt using 4/6 ductal occluder device. Child was on regular
follow up showing adequate growth parameters.
3.8. Splenic artery occlusion with a device
A 12 year old male case of hypersplenism with depressed cell
lines (pancytopenia) as a result of splenic sequestration. The
splenic artery was selectively profiled using an RCA catheter.
A supporting extra stiff wire was placed across the catheter
into the distal spleen. This was exchanged with the Mullins
sheath. A 10/12 ductal occluder device was deployed distally
in the splenic artery. The patient underwent successful oc-
clusion of the splenic artery and showed significant
improvement in the cell lines. Subsequently splenectomy was
done successfully for the patient.4. Follow-up
Follow-up data are summarized in individual tables. Mean
duration of follow up was 2.4 years (1 weeke7 years). It isrience with paravalvular devices.
Device type Device size Follow up
muscular device 10 mm 4 yrs
device Amplatzer 8/6 mm 9 yrs
device Amplatzer 8/6 mm 6 months
device Amplatzer 8/6 mm 6 years
Heart R 8/10, 2 vascular plugs 8/10 1 month
Table 7 e AP window device closure.
Age (yrs) Sex Device type Device size Follow up
1 3 yrs M PDA device
Lifetech
4/6 4 yrs
2 6 yrs M PDA device
Amplatzer
8/6 9 yrs
3 3 yrs F PDA device
Amplatzer
8/6 8 months
4 4 yrs M Abondend No
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Those who are lost to follow up include: 1 patient who un-
derwent ascending aortic perforation closure, and 1 patient
who underwent splenic sequestration. There were no shunts
detectable through or around the devices by transthoracic
echocardiography. There was also no evidence of thrombosis,
baffle (Fontan) obstruction, or new atrioventricular valve ste-
nosis or insufficiency.
1 patient with mitral paravalvular device closure with re-
sidual flow was readmitted 2 months following the procedure
with anemia. She improved symptomatically with blood
transfusion. Therewas no evidence of hemolysis in peripheral
smear, with no evidence of hematuria. Transthoracic echo-
cardiography was done in all patients on follow up. Device
was in situ with no residual flow in all except one with small
residual flow. Ventricular function was normal on follow up.
There was no evidence of new appearance of valve leak
(mitral, tricuspid or aortic), cardiac perforation, erosion of
aorta by device, device embolization or device distortion/
fracture. There was one procedure-related mortality in our
study group as elaborated under RSOV and no other major
complications were noted.5. Discussion
Devices utilized for ASD, VSD or PDA closure have now
generated a long term data showing their efficacy as a recog-
nized tool for closure of these defects. Encouraged by their
conventional usage these devices have now been used for
various other cardiac and extracardiac defects (unconven-
tional usage) especially in areas for which surgery was tradi-
tionally considered as the only therapeutic option.
Unconventional uses of devices may be divided into two
groups:1) Use of the devices for the lesions for which there are
no customized available devices (our group1, Table 1), 2) Use
of the devices for lesions which have customized devices
which necessitated the use of alternative strategy or devices.
This review attempts to review the available literature for the
same and to supplement the data with our own experience for
group1. Use of the devices for the lesions for which there are
no customized available devices includes: A) Coronary arte-
riovenous fistula, B) Pulmonary arteriovenous fistula, C) Sys-
temic arteriovenous fistula, D) Venovenous collateral, E)
Hepatic venovenous collateral, F) Ruptured sinus of Valsalva,
G) Aortic aneurysm, H) Pulmonary artery aneurysm, I) SCA
aneurysm closure, J) Occlusion of the artery, J1) Subclavian
artery occlusion, J2) Persistent LSVC occlusion, J3) MAPCA
occlusion (with Device), J4) Internal Iliac artery occlusion, K)AP window, M) LV aneurysm, L) Paravalvular leak, M) Fontan
fenestration, N) Possible closure of aorta to LV tunnel, O)
Bronchopleural fistula closure.5.1. Congenital coronary arteriovenous fistula
Non surgical closure of these fistulous communications is
now the accepted mode of therapy with numerous case
reports.1e5 The aim of the procedure should be to achieve
complete occlusion at as distal a location as possible, avoiding
any possibility of occluding branches to normal myocardium,
the largest device that fits in the smallest guiding catheter or
sheath is chosen. All varieties of coils, devices have been used
in the studies available. Although the uses of coil outnumber
the usage of devices in the literature. In our own cases we
have used PDA occluder devices, Gianturco coils and Vascular
plugs to close these fistulae. In two of our patients we used
both the coils and PDA device for the closure of the fistulae.
Our technique of the procedure, success rate and long term
follow up are similar to that available in the literature.5.2. Pulmonary arteriovenous fistulae, or malformations
(PAVMs)
A variety of percutaneous embolization techniques have been
successfully employed to address these lesions in the liter-
atue.6,7 The aim of the procedure is to occlude the artery
immediately before it enters the aneurysmal part. Coils, coil
bags, detachable balloons, double umbrellas and Amplatzer
devices have been utilized with different degrees of success to
occlude such fistulae over the last two decades and hence is a
well described enteity6,7 our experience was similar to that
observed in the literature. We used PDA occluder devices in 4
of the 8 patients who underwent closure of PAVM at our
institute with similar results for systemic AV fistulae.8-
e10Amplatzer device has been used interestingly as a
buttress to avoid embolization of coils. We used the same
technique in closing a large coronary artery fistula where de-
vice was deployed followed by placement of coils.5.3. Rupture of aneurysm of the sinus of Valsalva
(RSOV)
RSOV closure is a controversial area although initial reports of
small series indicate good immediate results.11e21The objec-
tion to the method of treatment is mainly related to the un-
derlying pathology. RSOV represents the weakness in the wall
of the sinuses leading to aneurysmal dilatation and subse-
quent rupture into any of the cardiac chambers viz. right
atrium, right ventricle, inter-ventricular septum or rarely left
ventricle. The surgical technique consists of closing the defect
and reinforcing the weak sinus wall. By Percutaneous tech-
nique although closure of the fistulous tract is achieved, no
attempts are made to correct the underlying pathology. There
is an anecdotal case of re-appearance of the flow after initial
successful closure of the same, emphasizing the theory that
long term effects need to be seen of the Percutaneous closure
of defects and that a close follow up of the patients who have
undergone the procedure is warranted. Very large defects
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was exemplified in one of our cases who had a fatal outcome.
5.4. Occlusion of the vessel
The occlusion of vessels such as subclavian artery occlusion,
splenic artery occlusion and closure of aortopulmonary col-
laterals are isolated cases and hence do not merit discussions.
Use of percutaneous closure avoided possible surgical inter-
vention in these cases.
5.5. AP window (APW)
The device selection plays a vital role in the selection of the
patient for suitability of a ductal occluder. The optimum de-
vice would depend upon the size of the defect as well as
relationship to surrounding structures especially coronary
arteries. The ductal occluder device has several desirable
characteristic for the APW such as ability to recapture and
reposition the device, high complete closure rates and rela-
tively smaller introducer sheaths.22e26 For a large hyperten-
sive APwindowmuscular VSD or ADO2may be useful.We had
used PDA devices for the same in all our patients.
5.6. Paraprosthetic leak
Symptomatic paraprosthetic leak can be treated with percu-
taneous transcatheter closure as an alternative to cardiac
surgery. Dedicated devices are not yet available, but once the
morphology of the leakage has been defined, it is possible to
choose among the existing devices that are currently used for
other percutaneous procedures.27e31 The availability of 3D
echocardiography has been observed by us to be particularly
useful in defining the morphology of the defect and hence in
selection of the device for the occlusion. In the aortic position:
The sizing of the defect have been by TEE although few have
used balloon sizing also. The commonest used device is PDA
occluder. Its distal disk remains in the left ventricle while the
proximal part is positioned inside the defect. Muscular VSD
device with its two disc have been used for larger defects as
we used it for one of our cases. In themitral position: for small
leaks Gianturco coil or Jackson coils (Cook, Inc) have been
used.29 For larger defects VSD or ASD device may be used.
They remain in place because the two disks assume an oval
rather than a circular position around the defect.31 In one case
we had used the vascular plug II and IV with stable position.
5.7. Fenestrated fontan
Circuit may prevent excessive increase in venous pressure in
the early post-operative phase, especially in high risk patients.
Many of these close spontaneously, however some remain
open causing persistent arterial desaturation and are poten-
tial cause of paradoxical embolism. Subsequent closure of the
fenestration using different transcatheter devices such as
ASD device and PDA device has been described. Percutaneous
devicewere easy to use, is easily retrieved prior to release, and
can be implanted into Fontan fenestrations with acceptable
procedure length and radiation time. The profile of the device
does not appear to alter blood flow through the bafflesignificantly. These results were well shown in a number of
case reports.32e35Conflicts of interest
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